» Articles » PMID: 14688313

The IL-12 Signature: NK Cell Terminal CD56+high Stage and Effector Functions

Overview
Journal J Immunol
Date 2003 Dec 23
PMID 14688313
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

We report that human peripheral NK cells expressing high CD56 levels (CD56(+high)) are terminally differentiated cells indistinguishable from mature NK cells recently activated in the presence of IL-12, and not a functionally distinct NK-cell subset or progenitors to mature CD56(+low) NK cells. CD56(+high) NK cells coexpress all differentiation Ags constitutive or inducible in mature (CD56(+)) NK cells, except CD16, present at lower level than on most mature NK cells. Also, activation markers, activating receptors and adhesion molecules, and most inducible receptors are expressed exclusively and constitutively and are inducible at higher levels on CD56(+high) than on CD56(+low) NK cells. Consistent with their activated phenotype, many CD56(+high) NK cells are cycling and mediate heightened effector functions (proliferation, IFN-gamma and IL-10 but not IL-13 production) in response to IL-12 and other NK cell-specific stimuli. Conversely, IL-12 induces on CD56(+low) NK cells all markers constitutively expressed on the CD56(+high) NK cells, concomitantly preventing the IL-2 (and IL-15)-inducible expression of NKp44 and CD16 re-expression after immune complex-induced down-modulation, and CD56(-/+low) NK cells acquire a CD56(+high) NK cell phenotype in short term in vitro culture with IL-12. The significance of these findings to the NK cell-mediated regulation of immune responses and NK cell development is discussed.

Citing Articles

BCG priming followed by a novel interleukin combination activates Natural Killer cells to selectively proliferate and become anti-tumour long-lived effectors.

Felgueres M, Esteso G, Garcia-Jimenez A, Dopazo A, Aguilo N, Mestre-Duran C Sci Rep. 2024; 14(1):13133.

PMID: 38849432 PMC: 11161620. DOI: 10.1038/s41598-024-62968-2.


Exploring NK cell receptor dynamics in paediatric leukaemias: implications for immunotherapy and prognosis.

Tu C, Buckle I, Leal Rojas I, Rossi G, Sester D, Moore A Clin Transl Immunology. 2024; 13(3):e1501.

PMID: 38525380 PMC: 10960520. DOI: 10.1002/cti2.1501.


Heightened metabolic responses in NK cells from patients with neuroblastoma suggests increased potential for immunotherapy.

Slattery K, Breheny M, Woods E, Keating S, Brennan K, Rooney C Front Oncol. 2022; 12:1004871.

PMID: 36276144 PMC: 9585418. DOI: 10.3389/fonc.2022.1004871.


Human Hepatic CD56 NK Cells Display a Tissue-Resident Transcriptional Profile and Enhanced Ability to Kill Allogenic CD8 T Cells.

Jameson G, Harmon C, Santiago R, Houlihan D, Gallagher T, Lynch L Front Immunol. 2022; 13:921212.

PMID: 35865550 PMC: 9295839. DOI: 10.3389/fimmu.2022.921212.


Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders.

Hue S, Ng S, Wang S, Tan S Cancers (Basel). 2022; 14(10).

PMID: 35626087 PMC: 9139583. DOI: 10.3390/cancers14102483.